reports
- Anthony Dick
- Michael Foundoukidis
- Emna Ben Bdira
- Maxime Kogge
Transaction in Own Shares
Transaction in Own Shares ENDEAVOUR ANNOUNCES TRANSACTION IN OWN SHARES London, 09 April 2025 – Endeavour Mining plc (LSE:EDV, TSX:EDV) (“the Company”) announces it has purchased the following number of its ordinary shares of USD 0.01 each from Stifel Nicolaus Europe Limited. Aggregated information Dates of purchase: 08 April 2025 Aggregate number of ordinary shares of USD 0.01 each purchased: 40,000 Lowest price paid per share (GBp): 1,710.00 Highest price paid per share (GBp): 1,751.00 Volume weighted average price paid per share (GBp): ...
OSE Immunotherapeutics présentera des données inédites de la période d...
OSE Immunotherapeutics présentera des données inédites de la période d’extension de Lusvertikimab à la “Digestive Disease Week” (DDW) 2025 OSE Immunotherapeutics présentera des données inédites de la période d’extension de Lusvertikimab à la “Digestive Disease Week” (DDW) 2025 Présentation de nouvelles données cliniques sur les bénéfices et la sécurité à long terme de l’anticorps monoclonal anti-IL-7R Lusvertikimab dans l’essai de Phase 2 d’extension dans la rectocolite hémorragique NANTES, France, 9 avril 2025, 7 heures 30 – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), un...
DEME signs agreement to acquire Norwegian offshore wind infrastructure...
DEME signs agreement to acquire Norwegian offshore wind infrastructure company Havfram DEME (Euronext: DEME) announced today that it has signed an agreement to acquire Havfram, an international offshore wind contractor based in Norway. This strategic acquisition aligns with DEME's ambition to expand its footprint in the offshore wind energy market and enhances its competitive positioning in turbine and foundation installations. Attachment
DEME tekent overeenkomst voor overname Noors wind infrastructuurbedrij...
DEME tekent overeenkomst voor overname Noors wind infrastructuurbedrijf Havfram DEME (Euronext: DEME) heeft vandaag aangekondigd dat het een overeenkomst heeft getekend om Havfram over te nemen, een internationale offshore windaannemer gevestigd in Noorwegen. Deze strategische overname sluit aan bij DEME's ambitie om zijn capaciteit in de offshore windenergiemarkt uit te breiden en versterkt zijn concurrentiepositie in turbine- en funderingsinstallaties. Bijlage
SBM Offshore signs US$400 million Sale and Leaseback agreement for FPS...
SBM Offshore signs US$400 million Sale and Leaseback agreement for FPSO Cidade de Paraty Amsterdam, April 9, 2025 SBM Offshore announces it has signed a non-recourse sale and leaseback financing agreement for FPSO Cidade de Paraty for the total amount of US$400 million and with a tenor of 8 years. The transaction is expected to be completed before the end of April 2025 following the fulfillment of certain closing conditions. FPSO Cidade de Paraty is owned by a special purpose company owned by affiliated companies of SBM Offshore (63.125%) and its partners (36.875%). Under the terms of th...
OSE Immunotherapeutics to Present Groundbreaking Extension Period Data...
OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025 OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025New Clinical Data from Phase 2 Extension Period in Ulcerative Colitis on Long-Term Benefits and Safety of Anti-IL-7R mAb Lusvertikimab NANTES, France – April 9, 2025, 7:30 a.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced that the Company will pres...
- Anthony Dick
- Michael Foundoukidis
ARYZTA veröffentlicht die Einladung zur ordentlichen Generalversammlun...
ARYZTA AG / Schlagwort(e): Generalversammlung ARYZTA veröffentlicht die Einladung zur ordentlichen Generalversammlung 2025 09.04.2025 / 07:00 CET/CEST About ARYZTA ARYZTA AG (‘ARYZTA’) ist ein weltweit tätiges Lebensmittelunternehmen mit einer führenden Position im Bereich Convenience-Backwaren. ARYZTA hat seinen Sitz in Schlieren, Schweiz, und ist in Europa, Asien, Australien und Neuseeland tätig. ARYZTA ist an der SIX Swiss Exchange kotiert (SIX: ARYN). Ende der Medienmitteilungen Sprache: Deutsch Unternehmen: ARYZTA AG Ifangstrasse 9 8952 Schlieren ...
ARYZTA issues AGM invitation
ARYZTA AG / Key word(s): AGMEGM ARYZTA issues AGM invitation 09.04.2025 / 07:00 CET/CEST About ARYZTA ARYZTA AG (‘ARYZTA’) is an international bakery company with a leadership position in convenience bakery. ARYZTA is based in Schlieren, Switzerland, with operations in Europe, Asia, Australia and New Zealand. ARYZTA is listed on the SIX Swiss Exchange (SIX: ARYN) End of Media Release Language: English Company: ARYZTA AG Ifangstrasse 9 8952 Schlieren Switzerland Phone: +41 (0) 44 583 42 00 E-mail: Internet: ISIN: CH0043238366 Valor: 4323836 List...
Medienmitteilung: Leonteq tritt in den Markt für börsenkotierte Hebelp...
Leonteq AG / Schlagwort(e): Markteinführung Medienmitteilung: Leonteq tritt in den Markt für börsenkotierte Hebelprodukte in der Schweiz ein 09.04.2025 / 07:01 CET/CEST MEDIENMITTEILUNG | LEONTEQ TRITT IN DEN MARKT FÜR BÖRSENKOTIERTE HEBELPRODUKTE IN DER SCHWEIZ EIN Zürich, 9. April 2025 Leonteq erweitert ihr Angebot im Schweizer Markt mit der Lancierung von börsenkotierten Hebelprodukten – ein bedeutender Meilenstein in der strategischen Expansion des Unternehmens. In den letzten Wochen hat Leonteq bereits über 2’500 Hebelprodukte an der SIX Swiss Exchange gelistet und p...
Press release: Leonteq enters the market for listed leverage products ...
Leonteq AG / Key word(s): Market Launch Press release: Leonteq enters the market for listed leverage products in Switzerland 09.04.2025 / 07:01 CET/CEST PRESS RELEASE | LEONTEQ ENTERS THE MARKET FOR LISTED LEVERAGE PRODUCTS IN SWITZERLAND Zurich, 9 April 2025 Leonteq today announced the official launch of its offering of listed leverage products in the Swiss market. This marks a significant milestone in the company’s strategic expansion. In the last few weeks, Leonteq has listed more than 2,500 leverage products on SIX Swiss Exchange and plans to significantly expand its ...
- Josseline Jenssen
Lucror Analytics - Convertibles Brief
In today's Convertibles Brief publication we comment on developments of the following high yield issuers: GOL
Convocation to the Annual Shareholders’ Meeting and the Special Shareh...
Convocation to the Annual Shareholders’ Meeting and the Special Shareholders’ Meeting of 9 May 2025 Press ReleaseRegulated Information09 April 2025, 7:00 am CET, Antwerp, Belgium The shareholders of VGP NV (the “Company”) are hereby invited to attend the annual shareholders’ meeting and the special shareholders’ meeting of the Company which shall consecutively take place at The Mills, Molenstraat 54, 2018 Antwerp, Belgium, on Friday 9 May 2025 at 10:00 am. Please consult the website link: for further information concerning the agenda, admission conditions and voting modalities for the Me...
Oproeping tot de Gewone Algemene Vergadering en de Bijzondere Algemene...
Oproeping tot de Gewone Algemene Vergadering en de Bijzondere Algemene Vergadering van Aandeelhouders van 9 mei 2025 PersberichtGereglementeerde informatie09 april 2025, 07h00, Antwerpen, België De aandeelhouders van VGP NV (de “Vennootschap”) worden hierbij uitgenodigd om deel te nemen aan de gewone algemene vergadering en de bijzondere algemene vergadering van de Vennootschap die achtereenvolgens zullen plaatsvinden te The Mills, Molenstraat 54, 2018 Antwerpen, België, op vrijdag 9 mei 2025 om 10.00 uur. Gelieve deze link: te raadplegen voor meer informatie over de agenda, de toelating...
Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Stu...
Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2 Saint Herblain (France) and Schlieren (Zurich), April 9, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and , a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participant has been vaccinated in a Phase 2 infant safety and immunogenicity study of Shigella4V2 (S4V2), the world’s most clinically advanced tetravalent bioconjugate vaccine candidate against shigellosis....
Valneva et LimmaTech annoncent la vaccination du premier participant à...
Valneva et LimmaTech annoncent la vaccination du premier participant à l’étude pédiatrique de Phase 2 du candidat vaccin tétravalent contre la shigellose S4V2 Saint Herblain (France) et Schlieren (Zurich), le 9 avril 2025 – (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, et , société de biotechnologies développant des vaccins pour la prévention de maladies potentiellement mortelles, ont annoncé aujourd’hui la vaccination du premier participant à l’essai pédiatrique de Phase 2 portant sur l’innocuité et l’immunogénicité de Shigella4V2 (S4V2), le candidat vaccin bi...
- Marc Hesselink
- CFA
- Thymen Rundberg
TomTom/No silver lining yet/HOLD
TomTom will report its 1Q25 results on Tuesday, 15 April. We are largely in line with consensus. Key point for the update is the trends in Automotive (very weak) and Enterprise (good). We have a mixed view on the investment case. We believe the platform improved a lot with the move to Orbis as underlined by the success with smaller Enterprise clients but with ongoing weakness in Automotive there is no room for significant profit growth. We reiterate our HOLD but lower our target price to €4.5 pe...
- David Vagman
- CFA
- Hans D’Haese
Exor/Committing to NAV per share growth/BUY
After the successful sale of 7m Ferrari shares for a total consideration of €3bn and taking into account Exor's €1bn share buyback (SBB), the rest of the proceeds are to be used to pursue diversification into the healthcare, luxury and technology sectors. This will balance the cyclical profile of Stellantis and CNHi (together 21% of NAV) and the overweight in Ferrari (43% of NAV). We see the upcoming investment as a catalyst for the stock considering its impressive track record while potential o...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.